Biotech Europe August 10, 2021Biotech companies continue to grow and attract major funding from both public and private sources. In 2020, global venture-capital funding and deals reached their highest ever level of $36.6 billion, while IPOs raised more than twice the amount of capital compared with 2019. We strive to provide individuals with disabilities equal access to our website. If you would like information about this content we will be happy to work with you. Please email us at: McKinsey_Website_Accessibility@mckinsey.com To read the article, see “Can European biotechs achieve greater scale in a fragmented landscape?” June 29, 2021.